UPDATE: FTC Deceptive CBD Advertising Consent Orders Approved

Print Friendly, PDF & Email

Recently, we wrote concerning six cannabidiol (“CBD”) companies (the “Sellers”) that had settled enforcement actions with the Federal Trade Commission (“FTC”). On March 5, 2021, following public comment, the FTC approved final administrative consent orders against the Sellers for engaging in deceptive CBD marketing practices. Although CBD was removed from the Controlled Substances Act (“CSA”) with the passage of the Agriculture Improvement Act of 2018 (the “Farm Bill”), to date, confusion remains as to what constitutes acceptable CBD advertising. To avoid running afoul of the law, businesses must consider various state and federal regulations (including regulations enforced by the FTC and Food and Drug Administration (“FDA”)) when advertising CBD products for sale to the public. 

How do the FTC and FDA regulate CBD Advertising?

The FTC and CBD Advertising

Unfair and deceptive advertising is prohibited by the FTC under Sections 5(a) and 12 of the FTC Act. In the cases at hand, the Sellers advertised that their respective CBD products were “medically proven” to treat pain without providing the requisite scientific evidence to substantiate such claims. The FTC specifically identifies as unlawful the use and publication of unproven marketing claims that are likely to “induce the purchase of food, drugs, devices, services, or cosmetics.” Had the Sellers procured “competent and reliable scientific evidence,” or “well-controlled human clinical studies substantiating that the claims are true,” they would not have found themselves the subject of FTC investigation. In general, CBD companies should abide by the simple rule that if their CBD advertising is “misleading in a material respect,” the FTC will consider it false adverting subject to enforcement action. 

The FDA and CBD Advertising

The Farm Bill preserved the FDA’s authority to regulate CBD products under the Federal Food, Drug and Cosmetics Act (the FD&C Act”) and Section 351 of the Public Health Services Act (the PHS Act”). The FDA has recently issued warning letters to CBD businesses that: (1) sell unapproved new drugs; and (2) misbrand their products. The FDA will deem a product misbranded if it is labeled in a false or misleading way, does not bear required labeling information, or is otherwise produced or packaged in a deceptive manner. Products that are found to violate the FD&C Act will be evaluated by the FDA to decide whether to initiate enforcement action. These factors include, among other things, then-existing FDA resources and the threat to public health. Additionally, the FDA may consult with other federal agencies and/or state law enforcement in making decisions about whether and how to enforce FD&C Act violations. In fact, the FTC and FDA often work together in investigating CBD advertising violations.

CBD companies that seek to advertise their CBD products should consult with a knowledgeable advertising attorney before launching any CBD marketing campaign. Failing to do so could result in an FTC or FDA investigation. 

If you are the subject of an FTC or FDA investigation or need assistance with a CBD product marketing campaign, please email us at info@kleinmoynihan.com, or call us at (212) 246-0900.

The material contained herein is provided for informational purposes only and is not legal advice, nor is it a substitute for obtaining legal advice from an attorney. Each situation is unique, and you should not act or rely on any information contained herein without seeking the advice of an experienced attorney. 

Attorney Advertising

Related Blog Posts:

TTAB Prohibits Registration of CBD Trademark

USPS Introduces New CBD Mailing Policy

USPTO Provides Clarity on CBD Trademark Applications

David O. Klein

David O. Klein

David Klein is one of the most recognized attorneys in the telemarketing, technology, Internet marketing, sweepstakes and telecommunications fields. Skilled at counseling clients on a broad range of technology-related matters, David Klein has substantial experience in negotiating and drafting complex licensing, marketing and Internet agreements.

Schedule a Call
In The Know

Trending Topics

New York Sweepstakes Law blog- Klein Moynihan Turco

New York Sweepstakes Law: Are You Compliant?

Print Friendly, PDF & Email

In general, a lottery exists when entrants pay for the chance to win a prize. States alone reserve the right to administer lotteries. Businesses can eliminate one element of what would otherwise be an illegal lottery, in order to transform it into a legal promotional game. If the requirement to

TCPA surveys

An Ad or not an Ad: NY Weighs in on TCPA Surveys

Print Friendly, PDF & Email

Another day, another court decision that refines constitutes a Telephone Consumer Protection Act (“TCPA”) unsolicited fax advertisement. A Manhattan-based federal court recently issued a decision that removes faxed invitations to participate in a survey from the TCPA definition of advertisement. In drawing this distinction for TCPA surveys, the Court held

NY sports gambling law- Klein Moynihan Turco

Agreement Reached to Enact NY Sports Gambling Law

Print Friendly, PDF & Email

This week, Governor Andrew Cuomo and the New York State Legislature agreed to a budget deal that will bring mobile sports betting to the State through a unique NY sports gambling law.  Upon the Governor’s signature, NY sports gambling is primed to become the nation’s largest market. However, New York

UK and US Social Media Influencer Laws

UK and US Social Media Influencer Laws

Print Friendly, PDF & Email

In September of 2020, the United Kingdom’s (“UK”) Committee of Advertising Practice (“CAP”) reviewed the Instagram accounts of 122 UK-based social media influencers to determine whether content was being properly flagged as advertising in accordance with applicable social media influencer laws. This past March, the UK Advertising Standards Authority (“ASA”)

Share on facebook
Share on google
Share on twitter
Share on linkedin